Loisance D, Sailly J C
Surgical Research Department, CHU H Mondor, Lille, France.
Eur J Anaesthesiol Suppl. 1993;8:9-13.
Cost-effectiveness, assessed in terms of cost/survivor and cost/additional day of survival, has been evaluated in two groups of patients awaiting cardiac transplantation: in six treated by mechanical support (mechanical bridge) and in 31 treated successfully by the addition of intravenous enoximone to previous existing inotropic support (pharmacological bridge). The mean cost per patient was $45,843, ranging from $38,326 in patients receiving pharmacological support to $84,683 in patients receiving mechanical support. The cost per patient transplanted after pharmacological support was $50,745. The mean cost per survivor at 1 year was $210,000 for all patients, ranging from $192,455 with pharmacological support to $254,000 with mechanical support. At 1 month, the cost per additional day of survival was higher (by 228%) in the mechanical support group than in the pharmacological support group.
已在两组等待心脏移植的患者中评估了成本效益，评估指标为成本/存活者以及成本/额外存活天数：一组6例患者接受机械支持（机械桥接）治疗，另一组31例患者在先前已有的正性肌力支持基础上添加静脉注射依诺昔酮进行成功治疗（药物桥接）。每位患者的平均成本为45,843美元，接受药物支持的患者成本为38,326美元，接受机械支持的患者成本为84,683美元。接受药物支持后进行移植的每位患者成本为50,745美元。所有患者1年时每位存活者的平均成本为210,000美元，药物支持组为192,455美元，机械支持组为254,000美元。在1个月时，机械支持组每额外存活一天的成本比药物支持组高（高228%）。
